Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
44 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00099437 | Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.(CONFIRM) | active not recruiting | Phase 3 | 736 | AstraZenecaINDUSTRY | 17 | Sep 14, 2026 | clinicaltrials |
| NCT00418886 | Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients(ZEAL) | completed | Phase 3 | 698 | Genzyme, a Sanofi CompanyINDUSTRY |
| 21 |
| Dec 31, 2024 |
| clinicaltrials |
| NCT06103409 | MSCs for the Treatment of Burn Wounds | unknown | Phase 1 / Phase 2 | 50 | Instituto Venezolano de Investigaciones CientificasOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06023277 | A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 40 | Jacinto Convit World Organization Inc.OTHER | 2 | Sep 5, 2023 | clinicaltrials |
| NCT00128310 | Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients | completed | Phase 3 | 252 | Spanish Breast Cancer Research GroupOTHER | 2 | May 31, 2023 | clinicaltrials |
| NCT01702571 | A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | completed | Phase 3 | 2,185 | Hoffmann-La RocheINDUSTRY | 43 | Apr 4, 2022 | clinicaltrials |
| NCT01566721 | A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SafeHER) | completed | Phase 3 | 2,577 | Hoffmann-La RocheINDUSTRY | 59 | Apr 27, 2021 | clinicaltrials |
| NCT00381095 | A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer(COPE) | terminated | Phase 4 | 152 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc.INDUSTRY | 19 | Jan 20, 2021 | clinicaltrials |
| NCT00471497 | A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)(ENESTnd) | completed | Phase 3 | 846 | Novartis PharmaceuticalsINDUSTRY | 35 | Nov 18, 2020 | clinicaltrials |
| NCT02862990 | Evaluation of the Attitude of Pre Menopausal Women With Breast Cancer Faced With the Risk of Fertility Loss Caused by Chemotherapy | completed | — | 343 | Latin American Cooperative Oncology GroupOTHER | 5 | Oct 5, 2020 | clinicaltrials |
| NCT01572038 | A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer(PERUSE) | completed | Phase 3 | 1,436 | Hoffmann-La RocheINDUSTRY | 39 | Sep 25, 2020 | clinicaltrials |
| NCT01533207 | Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery | terminated | Phase 3 | 38 | Gynecologic Oncology GroupNETWORK | 8 | Apr 28, 2020 | clinicaltrials |
| NCT01255150 | Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer | completed | — | 15 | National Cancer Institute (NCI)NIH | 5 | Nov 21, 2019 | clinicaltrials |
| NCT00876395 | Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer(BOLERO-1) | completed | Phase 3 | 719 | Novartis PharmaceuticalsINDUSTRY | 28 | Dec 19, 2018 | clinicaltrials |
| NCT01649856 | A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma | completed | Phase 3 | 572 | Hoffmann-La RocheINDUSTRY | 27 | Oct 11, 2017 | clinicaltrials |
| NCT00790036 | Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy(PILLAR2) | completed | Phase 3 | 742 | Novartis PharmaceuticalsINDUSTRY | 34 | Jul 12, 2017 | clinicaltrials |
| NCT01126892 | A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(ENACT) | completed | Phase 3 | 6 | Novartis PharmaceuticalsINDUSTRY | 2 | Feb 28, 2017 | clinicaltrials |
| NCT00237146 | Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy | completed | Phase 4 | 38 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00021255 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | completed | Phase 3 | 3,222 | SanofiINDUSTRY | 42 | Nov 15, 2016 | clinicaltrials |
| NCT02608060 | A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B | terminated | Phase 4 | 4 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02624141 | A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy | terminated | Phase 4 | 10 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00812175 | Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib(GIDEON) | completed | — | 3,371 | BayerINDUSTRY | 39 | Oct 17, 2016 | clinicaltrials |
| NCT00949910 | An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 4 | 6,586 | Hoffmann-La RocheINDUSTRY | 51 | Oct 5, 2016 | clinicaltrials |
| NCT00785785 | A Study of Nilotinib Versus Imatinib in GIST Patients(ENESTg1) | completed | Phase 3 | 644 | Novartis PharmaceuticalsINDUSTRY | 35 | Jun 16, 2016 | clinicaltrials |
| NCT00868140 | Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS)(PCOS) | terminated | N/A | 51 | Virginia Commonwealth UniversityOTHER | 2 | Jun 10, 2016 | clinicaltrials |
| NCT00451906 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. | completed | Phase 4 | 2,252 | Hoffmann-La RocheINDUSTRY | 40 | May 24, 2016 | clinicaltrials |
| NCT02533401 | A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 34 | Hoffmann-La RocheINDUSTRY | 2 | May 2, 2016 | clinicaltrials |
| NCT00681122 | CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach)(CARIATIDE) | completed | — | 2,600 | AstraZenecaINDUSTRY | 18 | Jan 18, 2016 | clinicaltrials |
| NCT00802841 | Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib(LASOR) | completed | Phase 3 | 191 | Novartis PharmaceuticalsINDUSTRY | 12 | Nov 16, 2015 | clinicaltrials |
| NCT02050594 | Ipilimumab 12-month Intensive Pharmacovigilance Protocol | completed | — | 6 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 7, 2015 | clinicaltrials |
| NCT00556322 | A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 424 | Hoffmann-La RocheINDUSTRY | 27 | Feb 23, 2015 | clinicaltrials |
| NCT00556712 | A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 889 | Hoffmann-La RocheINDUSTRY | 28 | Feb 11, 2015 | clinicaltrials |
| NCT00077025 | Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer | completed | Phase 2 | 174 | AstraZenecaINDUSTRY | 4 | Jul 16, 2014 | clinicaltrials |
| NCT00751036 | Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg(MACS0375) | terminated | Phase 3 | 94 | Novartis PharmaceuticalsINDUSTRY | 9 | Mar 26, 2014 | clinicaltrials |
| NCT00312208 | Docetaxel in Breast Cancer | completed | Phase 3 | 3,299 | SanofiINDUSTRY | 37 | Dec 30, 2013 | clinicaltrials |
| NCT01711476 | Meal Timing on Glucose and Hyperandrogenism in PCOS Women(MealTimePCOS) | unknown | N/A | 60 | Hospital de Clinicas CaracasOTHER | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00937547 | Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela(HPI) | completed | — | 329 | Instituto Oncologico Luis RazettiOTHER | 1 | Dec 4, 2012 | clinicaltrials |
| NCT00414024 | Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain. | terminated | Phase 3 | 11 | NovartisINDUSTRY | 6 | Apr 20, 2012 | clinicaltrials |
| NCT00171340 | Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer. | completed | Phase 3 | 1,065 | Novartis PharmaceuticalsINDUSTRY | 28 | Apr 16, 2012 | clinicaltrials |
| NCT00094029 | A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248 | approved for marketing | — | — | PfizerINDUSTRY | 34 | Mar 9, 2012 | clinicaltrials |
| NCT00130897 | Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma | approved for marketing | — | — | PfizerINDUSTRY | 50 | Mar 9, 2012 | clinicaltrials |
| NCT00035425 | Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection | completed | Phase 3 | 120 | PfizerINDUSTRY | 10 | Dec 1, 2009 | clinicaltrials |
| NCT00102219 | A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer | completed | Phase 2 | 77 | Eli Lilly and CompanyINDUSTRY | 7 | Nov 30, 2007 | clinicaltrials |
| NCT00035035 | A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. | completed | Phase 3 | — | Eli Lilly and CompanyINDUSTRY | 18 | Jul 19, 2006 | clinicaltrials |
Data updated 14 days agoSource updated unknownsource: clinicaltrials